このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

再発性または難治性の末梢性 T 細胞リンパ腫濾胞性バリアントまたは血管免疫芽球性 T 細胞リンパ腫の患者の治療における抗 ICOS モノクローナル抗体 MEDI-570

2026年11月17日 更新者:National Cancer Institute (NCI)

再発/難治性末梢性T細胞リンパ腫(PTCL)濾胞性バリアントおよび血管免疫芽球性T細胞リンパ腫(AITL)患者におけるMEDI-570の第I相試験

This phase I trial studies the side effects and best dose of anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570 in treating patients with peripheral T-cell lymphoma follicular variant or angioimmunoblastic T-cell lymphoma that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as anti-ICOS monoclonal antibody MEDI-570, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread.

調査の概要

状態

積極的、募集していない

介入・治療

詳細な説明

PRIMARY OBJECTIVE:

I. To determine the safety, maximum tolerated dose and recommended phase II dose (RP2D) of anti-ICOS monoclonal antibody MEDI-570 (MEDI-570) in patients with refractory/relapsed peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), follicular lymphoma, mycosis fungoides (MF) and cutaneous T-cell lymphomas (CTCL).

SECONDARY OBJECTIVES:

I. To evaluate the pharmacokinetic profile of MEDI-570. II. To evaluate the overall response rate (ORR) and progression free survival (PFS) of MEDI-570 at all dose levels and in a 10-patient expansion cohort at the maximum tolerated dose (MTD).

III. To determine short and long term effects of MEDI-570 at all dose levels on the immune system and on T-cell lymphocyte subsets.

IV. To determine the relationship between ICOS expression on tumor cells and response to MEDI-570.

EXPLORATORY OBJECTIVE:

I. To evaluate biomarkers of response and resistance to MEDI-570 in the study population.

OUTLINE: This is a dose-escalation study.

Patients receive anti-ICOS monoclonal antibody MEDI-570 intravenously (IV) over 1-4 hours on day 1. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days and then every 6 weeks for 12 weeks.

研究の種類

介入

入学 (実際)

23

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • California
      • Duarte、California、アメリカ、91010
        • City of Hope Comprehensive Cancer Center
      • Sacramento、California、アメリカ、95817
        • University of California Davis Comprehensive Cancer Center
    • Connecticut
      • New Haven、Connecticut、アメリカ、06520
        • Yale University
      • New Haven、Connecticut、アメリカ、06510
        • Smilow Cancer Center/Yale-New Haven Hospital
    • Florida
      • Tampa、Florida、アメリカ、33612
        • Moffitt Cancer Center
    • Illinois
      • Chicago、Illinois、アメリカ、60637
        • University of Chicago Comprehensive Cancer Center
    • Kansas
      • Fairway、Kansas、アメリカ、66205
        • University of Kansas Clinical Research Center
    • Kentucky
      • Lexington、Kentucky、アメリカ、40536
        • University of Kentucky/Markey Cancer Center
    • Missouri
      • Creve Coeur、Missouri、アメリカ、63141
        • Siteman Cancer Center at West County Hospital
      • St Louis、Missouri、アメリカ、63110
        • Washington University School of Medicine
      • St Louis、Missouri、アメリカ、63129
        • Siteman Cancer Center-South County
    • Nebraska
      • Omaha、Nebraska、アメリカ、68198
        • University of Nebraska Medical Center
    • New York
      • Buffalo、New York、アメリカ、14263
        • Roswell Park Cancer Institute
      • The Bronx、New York、アメリカ、10461
        • Montefiore Medical Center-Einstein Campus
      • The Bronx、New York、アメリカ、10467
        • Montefiore Medical Center - Moses Campus
      • The Bronx、New York、アメリカ、10461
        • Montefiore Medical Center-Weiler Hospital
    • North Carolina
      • Durham、North Carolina、アメリカ、27710
        • Duke University Medical Center
    • Ohio
      • Columbus、Ohio、アメリカ、43210
        • Ohio State University Comprehensive Cancer Center
    • Texas
      • Dallas、Texas、アメリカ、75390
        • UT Southwestern/Simmons Cancer Center-Dallas
      • Houston、Texas、アメリカ、77030
        • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
    • Utah
      • Salt Lake City、Utah、アメリカ、84112
        • Huntsman Cancer Institute/University of Utah
    • British Columbia
      • Vancouver、British Columbia、カナダ、V5Z 4E6
        • BCCA-Vancouver Cancer Centre
    • Ontario
      • Toronto、Ontario、カナダ、M5G 2M9
        • University Health Network-Princess Margaret Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Pathologic diagnosis of one of the following:

    • For dose escalation:

      • Confirmed diagnosis of peripheral T-cell lymphoma (PTCL) or angioimmunoblastic T-cell lymphoma (AITL) that is refractory to at least one line of therapy; anaplastic large cell lymphoma (ALCL) and natural killer T-cell lymphoma nasal type (NKTCL) are excluded

      • Advanced stage cutaneous T-cell lymphoma (CTCL), specifically CTCL NOS, small/medium T-cell lymphoma (SMTCL) and mycosis fungoides (MF) stage IB, IIA, IIB, III and IV that have relapsed after at least one specific prior therapy (e.g. interferon, photopheresis, denileukin difitox, bexarotene, etc); anaplastic cutaneous large cell lymphoma (ACLCL) and lymphomatoid papulopsis are excluded

      • Follicular lymphoma grade 1, 2 or 3A that meets the following criteria:

        • Relapsed or refractory to at least 2 lines of therapy AND
        • Relapsed or refractory post autologous cell transplantation (HCT)
    • For dose expansion/dose confirmation phase:

      • Patients with confirmed diagnosis of peripheral T-cell lymphoma (PTCL) follicular type or angioimmunoblastic T-cell lymphoma (AITL) that is refractory to at least one line of therapy
  • At least 14 days from the last therapy dose or 5 half-lives (whichever is shorter), and resolution of toxicity related to the last therapy, excluding grade 2 or less peripheral neuropathy and alopecia; for radiation therapy, a minimum of 2 weeks and resolution of all acute toxicity will be required

  • Patients must have at least one measurable lesion that can be accurately measured with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI) scan, or physical exam (by calipers only); (PTCL, AITL and follicular lymphoma patients will be assessed on this study using the Lugano criteria for the evaluation of lymphomas; CTCL and MF patients will be assessed using International Society for Cutaneous Lymphomas [ISCL] and European Organization for Research and Treatment of Cancer [EORTC] criteria)

  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)

  • Life expectancy of greater than 6 months

  • Leukocytes >= 3,000/mcL

  • Hemoglobin >= 80 d/L (or >= 8 g/dL)

    • Patients must not have received a transfusion, with packed red blood cells, within 2 weeks prior to sample being collected
  • Absolute neutrophil count (ANC) >= 1,500/mcL

  • Platelets (PLT) >= 50,000/mcL

  • Absolute CD4 count > 100 cells/uL

  • Total bilirubin < 1.5 upper limit of normal (ULN)

  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x institutional upper limit of normal

  • Creatinine < 1.5 mg/dl (= 132 umol/L) or

  • Creatinine clearance >= 50 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal

  • In patients with bone marrow involvement the minimum requirement is as follows:

    • Leukocytes >= 2000/mcL
    • ANC >= 1000/mcL
    • PLT >= 50 000/mcL
  • Availability of tissue for correlative studies; patients must have at least 6-8 unstained slides of archived formalin-fixed, paraffin-embedded tumor tissue available; if not enough archived tissue is available, a fresh tumor biopsy prior to study initiation is mandatory; for patients who have undergone a fresh baseline biopsy at baseline, the archived tissue is not mandatory

  • The effects of MEDI-570 on the developing human fetus are unknown; for this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, during the study participation, and for 3 months after the last dose of the drug; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must have either had a prior vasectomy or agree to use effective contraception prior to the study, during the study, and for 3 months after the last dose of the drug; males should avoid fathering children during and for at least three months after therapy is completed

  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Patients who are receiving any other investigational agents

  • Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events

  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to MEDI-570 or history of anaphylaxis to any biological component

  • Any history or evidence of opportunistic infection within 6 months of screening including tuberculosis, severe cytomegalovirus (CMV) or herpetic infections (such as disseminated herpes, herpes encephalitis, ophthalmic herpes)

  • Evidence of active infection by hepatitis B and/or C; active viral infection by hepatitis B and hepatitis C could be associated with cytopenias (due to hypersplenism or due to the active virus itself), which could add further risk when a potential immunosuppressive medication is used; for patients with hepatitis B treated with anti-virals to undetectable viral load, and for patients with hepatitis C with undetectable ribonucleic acid (RNA) levels and no evidence of liver damage, enrollment may be considered and should discuss first with study's principal investigator

  • History of human immunodeficiency virus (HIV) infection; the human immunodeficiency virus (HIV) depletes CD4 T-cells and could also have a role in T-cell anergy; since MEDI-570 preferentially affects CD4 T-cell numbers and function, and the resultant immunosuppression by this agent can be prolonged, exposing HIV patients to MEDI-570 will place them in an unnecessary risk of developing infections due to an underlying acquired cellular immunity defect

  • History of primary immunodeficiency

  • Receipt of live or live attenuated vaccine within 12 weeks prior to enrollment

  • All potential patients must undergo a tuberculosis (TB) test prior to study entry to rule out active or latent tuberculosis (either purified protein derivative [PPD] or QuantiFERON-TB Gold, whichever is preferred and available at the institution); patients with a history of TB (even if treated), or evidence of active or latent TB, are excluded; the diagnosis of active TB is defined per current guidelines; patients with a positive TB test (e.g. PPD or QuantiFERON-TB Gold) will be excluded; patients with history of Bacille-Calmette-Guerin (BCG) vaccination will be tested with QuantiFERON-TB Gold test in order to rule out exposure to TB

  • Patients who have undergone allogeneic stem cell transplantation

  • Patients who have undergone autologous stem cell transplantation within 3 months from study entry

  • Major surgery within 30 days prior or during the study period

  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

  • Pregnant women are excluded from this study due to the potential toxicity in pre-clinical reproductive studies; in addition, there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with MEDI-570; breastfeeding should be discontinued if the mother is treated with MEDI-570

  • Patients with active, known, or suspected autoimmune disease, except in these conditions:

    • Participants with well-controlled asthma and/or mild allergic rhinitis (seasonal allergies) are eligible

    • Participants with the following disease conditions are also eligible:

      • Vitiligo,
      • Type 1 diabetes mellitus
      • Residual hypothyroidism due to autoimmune condition only requiring hormone replacement
      • Euthyroid participants with a history of Grave's disease (participants suspected autoimmune thyroid disorders must be negative for thyroglobulin and thyroid peroxidase antibodies and thyroid stimulating immunoglobulin prior to first dose of study drug)
      • For patients with ITP (idiopathic thrombocytopenic purpura) or AIHA (autoimmune hemolytic anemia), a case by case discussion with study principal investigator (PI) may be considered
      • Patients not receiving systemic therapy (i.e., systemic steroids or biologic therapy with disease modifying anti-rheumatic drugs [DMARDs]) within 2 years can be also eligible
  • Patients with a weight of < 39 kg

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Treatment (MEDI-570)

Patients receive anti-ICOS monoclonal antibody MEDI-570 IV over 1-4 hours on day 1. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.

Correlative studies

Correlative studies

Given IV

他の名前:
  • MEDI-570

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Incidence of toxicity and safety of anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570
時間枠:Up to 12 weeks after completion of study treatment

Graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Frequency and severity of adverse events will be tabulated using counts and proportions detailing frequently occurring, serious and severe events of interest. Adverse events will be summarized using all adverse events experienced, although a sub-analysis may be conducted including only those adverse events in which the treating physician deems possibly, probably or definitely attributable to one or both study treatments.

Up to 12 weeks after completion of study treatment
Maximum tolerated dose (MTD) of anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570
時間枠:Up to 21 days

Toxicity will be assessed using the NCI CTCAE, version 5.0.

Up to 21 days
Recommended phase 2 dose of anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570
時間枠:Up to 21 days

Toxicity will be assessed using the NCI CTCAE, version 5.0.

Up to 21 days

二次結果の測定

結果測定
メジャーの説明
時間枠
Pharmacokinetics (PK), such as plasma concentration and PK parameters, of monoclonal antibody therapy
時間枠:Prior to dose on day 1, immediately after dose, and at 6 minutes, 24, 48 and 72 hours post dose of cycle 1 and cycle 2, and then on day 1 pre-dose of every subsequent cycle

Attempts to model associations between pharmacokinetic data with toxicity profiles will be performed primarily using descriptive statistics; however, logistic regression may be used if warranted.

Prior to dose on day 1, immediately after dose, and at 6 minutes, 24, 48 and 72 hours post dose of cycle 1 and cycle 2, and then on day 1 pre-dose of every subsequent cycle
Overall response rate
時間枠:Up to 36 weeks

Assessed per the Revised Response Criteria for Malignant Lymphoma of the Lugano Classification. Summary statistics, such as the mean, median, counts and proportion, will be used to describe patients' clinical characteristics. For all statistical tests, two-sided tests will be performed and no p-value adjustment performed due to the exploratory nature of these tests. A p-value of 0.05 or less will be considered statistically significant.

Up to 36 weeks
Progression-free survival
時間枠:Up to 12 weeks after completion of study treatment

Summary statistics, such as the mean, median, counts and proportion, will be used to describe patients' clinical characteristics. For all statistical tests, two-sided tests will be performed and no p-value adjustment performed due to the exploratory nature of these tests. A p-value of 0.05 or less will be considered statistically significant.

Up to 12 weeks after completion of study treatment
Immunogenicity
時間枠:Up to 36 weeks

Summary statistics, such as the mean, median, counts and proportion, will be used to describe patients' clinical characteristics. For all statistical tests, two-sided tests will be performed and no p-value adjustment performed due to the exploratory nature of these tests. A p-value of 0.05 or less will be considered statistically significant.

Up to 36 weeks
Overall survival (OS)
時間枠:Up to 12 weeks after completion of study treatment

Summary statistics, such as the mean, median, counts and proportion, will be used to describe patients' clinical characteristics. For all statistical tests, two-sided tests will be performed and no p-value adjustment performed due to the exploratory nature of these tests. A p-value of 0.05 or less will be considered statistically significant.

Up to 12 weeks after completion of study treatment

その他の成果指標

結果測定
メジャーの説明
時間枠
Biomarkers of response and resistance to anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570
時間枠:Up to 36 weeks

Predictors of clinical outcomes will be investigated using logistic regression, Cox proportional hazards regression and/or generalized estimating equations as appropriate. Potential predictors include clinical predictors and molecular correlates. Descriptive statistics and plotting of data will also be used to better understand potential relationships.

Up to 36 weeks

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Julio C Chavez、University Health Network Princess Margaret Cancer Center LAO

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2016年9月13日

一次修了 (実際)

2024年12月18日

研究の完了 (推定)

2026年12月24日

試験登録日

最初に提出

2015年8月10日

QC基準を満たした最初の提出物

2015年8月10日

最初の投稿 (推定)

2015年8月13日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月18日

QC基準を満たした最後の更新が送信されました

2026年11月17日

最終確認日

2026年6月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • NCI-2015-01271
  • UM1CA186644 (米国 NIH グラント/契約)
  • NCI-2015-01271 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
  • PJC-021
  • 9930 (その他の識別子:CTEP)
  • 9930 (その他の識別子:University Health Network Princess Margaret Cancer Center LAO)

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。